[
  {
    "ts": null,
    "headline": "Dow Loses About 350 Points After Record-Breaking Run",
    "summary": "A slide in shares of pharmaceutical firm  Merck  and biotech company  Amgen  helped drag the blue-chip index back from the highs notched in the broad rally Friday after Federal Reserve Chair  Jerome Powell  signaled that the central bank could lower interest rates next month.  The Dow fell 0.8%, with Merck losing 2.4% and Amgen falling 1.8%.  “There is some lack of comfort that Powell’s assertion that tariffs will be mostly a one-time increase in prices will be how things actually play out,” wrote  Louis Navellier,  chief investment officer of Navellier & Associates, in a Monday note.",
    "url": "https://finnhub.io/api/news?id=ef73ff0b2f68a5d9975a5b189d83cbeebe7b147173e27cb8e4a366e9a666040f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756154220,
      "headline": "Dow Loses About 350 Points After Record-Breaking Run",
      "id": 136523948,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "A slide in shares of pharmaceutical firm  Merck  and biotech company  Amgen  helped drag the blue-chip index back from the highs notched in the broad rally Friday after Federal Reserve Chair  Jerome Powell  signaled that the central bank could lower interest rates next month.  The Dow fell 0.8%, with Merck losing 2.4% and Amgen falling 1.8%.  “There is some lack of comfort that Powell’s assertion that tariffs will be mostly a one-time increase in prices will be how things actually play out,” wrote  Louis Navellier,  chief investment officer of Navellier & Associates, in a Monday note.",
      "url": "https://finnhub.io/api/news?id=ef73ff0b2f68a5d9975a5b189d83cbeebe7b147173e27cb8e4a366e9a666040f"
    }
  },
  {
    "ts": null,
    "headline": "Royalty Pharma (RPRX) Acquires US$885 Million Royalty Interest In Amgen's Imdelltra",
    "summary": "Royalty Pharma (RPRX) recently acquired a royalty interest in Amgen's Imdelltra, a move that may have added confidence to investors, contributing to the company's 11% share price increase over the last quarter. This acquisition, along with its royalty sharing arrangements and the drug's anticipated market success, illustrates Royalty Pharma’s strategic business expansion. Concurrently, it saw enhancements in its board composition with new appointments, which might have played a beneficial...",
    "url": "https://finnhub.io/api/news?id=a918fa09845af4c13d6160479161bd729f070702bb85f2c581237d5a2aa82be5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756143019,
      "headline": "Royalty Pharma (RPRX) Acquires US$885 Million Royalty Interest In Amgen's Imdelltra",
      "id": 136522507,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Royalty Pharma (RPRX) recently acquired a royalty interest in Amgen's Imdelltra, a move that may have added confidence to investors, contributing to the company's 11% share price increase over the last quarter. This acquisition, along with its royalty sharing arrangements and the drug's anticipated market success, illustrates Royalty Pharma’s strategic business expansion. Concurrently, it saw enhancements in its board composition with new appointments, which might have played a beneficial...",
      "url": "https://finnhub.io/api/news?id=a918fa09845af4c13d6160479161bd729f070702bb85f2c581237d5a2aa82be5"
    }
  },
  {
    "ts": null,
    "headline": "BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up",
    "summary": "BeOne Medicines Ltd. (NASDAQ:ONC) on Monday agreed to sell its royalty rights on the worldwide sales, excluding China, of Amgen Inc.’s (NASDAQ:AMGN) Imdelltra (tarlatamab-dlle) for up to $950 million to Royalty Pharma Inc. (NASDAQ:RPRX). Under the terms of the agreement, BeOne will receive an upfront payment of $885 million, with the option to sell remaining royalties within 12 months for up to $65 million. BeOne will share in a portion of the royalty on annual sales above $1.5 billion, and will",
    "url": "https://finnhub.io/api/news?id=966ecf221f7f4dbcf937b93c10040c9de2bd27a97fd091cf657075eb3cc9418d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756142369,
      "headline": "BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up",
      "id": 136522508,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "BeOne Medicines Ltd. (NASDAQ:ONC) on Monday agreed to sell its royalty rights on the worldwide sales, excluding China, of Amgen Inc.’s (NASDAQ:AMGN) Imdelltra (tarlatamab-dlle) for up to $950 million to Royalty Pharma Inc. (NASDAQ:RPRX). Under the terms of the agreement, BeOne will receive an upfront payment of $885 million, with the option to sell remaining royalties within 12 months for up to $65 million. BeOne will share in a portion of the royalty on annual sales above $1.5 billion, and will",
      "url": "https://finnhub.io/api/news?id=966ecf221f7f4dbcf937b93c10040c9de2bd27a97fd091cf657075eb3cc9418d"
    }
  },
  {
    "ts": null,
    "headline": "Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks",
    "summary": "The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?",
    "url": "https://finnhub.io/api/news?id=54833fc62f377fd1cb2d9eb3b28af15a2f75c9547ade5786483f5a2b83b9da3f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756127402,
      "headline": "Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks",
      "id": 136522509,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?",
      "url": "https://finnhub.io/api/news?id=54833fc62f377fd1cb2d9eb3b28af15a2f75c9547ade5786483f5a2b83b9da3f"
    }
  },
  {
    "ts": null,
    "headline": "REPATHA® NOW INDICATED FOR ADULTS AT INCREASED RISK FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS DUE TO UNCONTROLLED LDL-C",
    "summary": "Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha® (evolocumab) to include adults at increased risk for major adverse cardiovascular events (MACE) due to uncontrolled low-density lipoprotein cholesterol (LDL-C), commonly known as 'bad cholesterol.' The update removes a prior requirement for a patient to have been diagnosed with cardiovascular (CV) disease.",
    "url": "https://finnhub.io/api/news?id=3db8f8f954c165225c10f976c30f25cce0bc2fe2703da35e8f2da7ca25958662",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756126800,
      "headline": "REPATHA® NOW INDICATED FOR ADULTS AT INCREASED RISK FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS DUE TO UNCONTROLLED LDL-C",
      "id": 136508128,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha® (evolocumab) to include adults at increased risk for major adverse cardiovascular events (MACE) due to uncontrolled low-density lipoprotein cholesterol (LDL-C), commonly known as 'bad cholesterol.' The update removes a prior requirement for a patient to have been diagnosed with cardiovascular (CV) disease.",
      "url": "https://finnhub.io/api/news?id=3db8f8f954c165225c10f976c30f25cce0bc2fe2703da35e8f2da7ca25958662"
    }
  },
  {
    "ts": null,
    "headline": "Royalty Pharma buys BeOne stake in Amgen lung cancer drug sales",
    "summary": "An $885M deal with BeOne Medicine gives the pharma financier rights to a revenue stream from global sales of Imdelltra, which is sold by Amgen.",
    "url": "https://finnhub.io/api/news?id=615442e1016760317361892820e83294a56312fb6c2cfb32f8430c10c58e8cb0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756124980,
      "headline": "Royalty Pharma buys BeOne stake in Amgen lung cancer drug sales",
      "id": 136522510,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "An $885M deal with BeOne Medicine gives the pharma financier rights to a revenue stream from global sales of Imdelltra, which is sold by Amgen.",
      "url": "https://finnhub.io/api/news?id=615442e1016760317361892820e83294a56312fb6c2cfb32f8430c10c58e8cb0"
    }
  },
  {
    "ts": null,
    "headline": "Dow's nearly 250-point fall led by losses for shares of Merck, Sherwin-Williams Co.",
    "summary": "Dow's nearly 250-point fall led by losses for shares of Merck, Sherwin-Williams Co.",
    "url": "https://finnhub.io/api/news?id=7aa241ab7c2ce1d8ae7bfc08d74b41adebb2a4bbe3b469035f1aa4153ab3640c",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756122360,
      "headline": "Dow's nearly 250-point fall led by losses for shares of Merck, Sherwin-Williams Co.",
      "id": 136528035,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Dow's nearly 250-point fall led by losses for shares of Merck, Sherwin-Williams Co.",
      "url": "https://finnhub.io/api/news?id=7aa241ab7c2ce1d8ae7bfc08d74b41adebb2a4bbe3b469035f1aa4153ab3640c"
    }
  },
  {
    "ts": null,
    "headline": "Royalty Pharma to pay up to $950 million for royalties from Amgen's lung cancer drug",
    "summary": "The deal gives Royalty Pharma access to roughly 7% of global net sales of the therapy, Imdelltra, which won U.S. approval last year for patients with extensive-stage small cell lung cancer who have failed chemotherapy.  Royalty Pharma will pay $885 million upfront, while Chinese drug developer BeOne will retain an option to sell an additional portion for up to $65 million within the next 12 months.  BeOne, formerly known as BeiGene, will keep commercial rights to the therapy in China.",
    "url": "https://finnhub.io/api/news?id=e11f0958583b3f105f31d251134c171ea4d5f1589961e2daefe9df7d6085e0db",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756117999,
      "headline": "Royalty Pharma to pay up to $950 million for royalties from Amgen's lung cancer drug",
      "id": 136508129,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The deal gives Royalty Pharma access to roughly 7% of global net sales of the therapy, Imdelltra, which won U.S. approval last year for patients with extensive-stage small cell lung cancer who have failed chemotherapy.  Royalty Pharma will pay $885 million upfront, while Chinese drug developer BeOne will retain an option to sell an additional portion for up to $65 million within the next 12 months.  BeOne, formerly known as BeiGene, will keep commercial rights to the therapy in China.",
      "url": "https://finnhub.io/api/news?id=e11f0958583b3f105f31d251134c171ea4d5f1589961e2daefe9df7d6085e0db"
    }
  },
  {
    "ts": null,
    "headline": "Royalty Pharma to Acquire Royalty Interest in Amgen’s Imdelltra for up to $950 Million",
    "summary": "Imdelltra is a first-in-class immunotherapy for the treatment of extensive-stage small cell lung cancer (ES-SCLC) marketed by AmgenRoyalty Pharma to pay $885 million upfront; BeOne Medicines to retain a $65 million option to sell additional portion of its royalty NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a royalty interest in Amgen’s Imdelltra, a first-in-class DLL3 targeting bispecific T-cell engager (BiTE), from BeOne Med",
    "url": "https://finnhub.io/api/news?id=d2344ad1cb19c1b053d4b7bc9901efaf249b52d02946b1954ad9a3358805236f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756116600,
      "headline": "Royalty Pharma to Acquire Royalty Interest in Amgen’s Imdelltra for up to $950 Million",
      "id": 136508130,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Imdelltra is a first-in-class immunotherapy for the treatment of extensive-stage small cell lung cancer (ES-SCLC) marketed by AmgenRoyalty Pharma to pay $885 million upfront; BeOne Medicines to retain a $65 million option to sell additional portion of its royalty NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a royalty interest in Amgen’s Imdelltra, a first-in-class DLL3 targeting bispecific T-cell engager (BiTE), from BeOne Med",
      "url": "https://finnhub.io/api/news?id=d2344ad1cb19c1b053d4b7bc9901efaf249b52d02946b1954ad9a3358805236f"
    }
  },
  {
    "ts": null,
    "headline": "BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million",
    "summary": "SAN CARLOS, Calif., August 25, 2025--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it has entered into an agreement to sell its royalty rights on the worldwide sales, excluding China, of Amgen’s IMDELLTRA® (tarlatamab-dlle) for up to $950 million to Royalty Pharma (Nasdaq: RPRX).",
    "url": "https://finnhub.io/api/news?id=0e99ddfb1581f680ab4e4d223a0d7b112cecbf54a004445ffbe5ce37753fdb55",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756116000,
      "headline": "BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million",
      "id": 136508131,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "SAN CARLOS, Calif., August 25, 2025--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it has entered into an agreement to sell its royalty rights on the worldwide sales, excluding China, of Amgen’s IMDELLTRA® (tarlatamab-dlle) for up to $950 million to Royalty Pharma (Nasdaq: RPRX).",
      "url": "https://finnhub.io/api/news?id=0e99ddfb1581f680ab4e4d223a0d7b112cecbf54a004445ffbe5ce37753fdb55"
    }
  }
]